57644-54-9 | Gastrodenol

Packsize	Purity	Availability	Price	Discounted Price
1g	35%	in stock	$11.00	$8.00
5g	35%	in stock	$13.00	$9.00
10g	35%	in stock	$19.00	$14.00
25g	35%	in stock	$23.00	$17.00
100g	35%	in stock	$78.00	$55.00

Description

• Catalog Number: AI68589
• Chemical Name: Gastrodenol
• CAS Number: 57644-54-9
• Molecular Formula: C12H10BiK3O14
• Molecular Weight: 704.4747
• MDL Number: MFCD02101411
• SMILES: [O-]C(=O)C(CC(=O)[O-])(CC(=O)[O-])O.[O-]C(=O)C(CC(=O)[O-])(CC(=O)[O-])O.[K+].[K+].[K+].[Bi+3]

Computed Properties

• Complexity: 211
• Covalently-Bonded Unit Count: 6
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 14
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4

Literature

• Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population.

  Helicobacter 20121201

• Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.

  World journal of gastroenterology 20120828

• Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention effects by H. pylori eradication.

  The British journal of nutrition 20120701

• Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.

  Singapore medical journal 20120401

• Bismuth ions inhibit the biological activity of non-amidated gastrins in vivo.

  Biochemical pharmacology 20120215

• A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.

  Helicobacter 20120201

• Is quadruple therapy the new triple therapy for H pylori?

  Canadian family physician Medecin de famille canadien 20120101

• Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.

  Helicobacter 20110801

• Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.

  Medicine 20110501

• Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study.

  Alimentary pharmacology & therapeutics 20110401

• Studies of distribution and recurrence of Helicobacter spp. gastric mucosa of dogs after triple therapy.

  Acta cirurgica brasileira 20110401

• Quadruple or triple therapy to eradicate H pylori.

  Lancet (London, England) 20110312

• Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.

  Lancet (London, England) 20110312

• [Rifaximin in combined treatment of the Helicobacter pylori infection in childhood].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20110101

• [Helicobacter pylori: what schemes of eradication are essential today?].

  Terapevticheskii arkhiv 20110101

• Considerable use of furazolidone in Iran.

  Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20101001

• Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance.

  Journal of digestive diseases 20101001

• Case of the month. MALT lymphoma.

  JAAPA : official journal of the American Academy of Physician Assistants 20101001

• Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.

  Journal of gastrointestinal cancer 20100901

• Helicobacter pylori infection.

  The New England journal of medicine 20100805

• High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

  Helicobacter 20100601

• Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.

  Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20100101

• Parallel on-line detection of a methylbismuth species by hyphenated GC/EI-MS/ICP-MS technique as evidence for bismuth methylation by human hepatic cells.

  Metallomics : integrated biometal science 20100101

• Effect of bismuth citrate, lactose, and organic acid on necrotic enteritis in broilers.

  Poultry science 20091101

• Peptic ulcer disease.

  Lancet (London, England) 20091024

• A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine.

  World journal of gastroenterology 20091007

• Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

  Digestive diseases and sciences 20090901

• Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children.

  Digestive diseases and sciences 20090801

• High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20090801

• Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate?

  Helicobacter 20090801

• Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.

  The Journal of antimicrobial chemotherapy 20090501

• Determination of trimethylbismuth in the human body after ingestion of colloidal bismuth subcitrate.

  Drug metabolism and disposition: the biological fate of chemicals 20090201

• Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.

  The American journal of gastroenterology 20090101

• Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.

  Wiener klinische Wochenschrift 20090101

• [Combined treatment of gastric ulcers induced by nonsteroid antiinflammatory drugs. Results of 4-week population-based controlled trial of efficacy of proton pump inhibitor combination with tripotassium bismuth dicitrate].

  Terapevticheskii arkhiv 20090101

• [Rifaksimin in complex treatment of Helicobacter pylori infection in children (a pilot study)].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20090101

• Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.

  Helicobacter 20081201

• Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

  World journal of gastroenterology 20081028

• Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital.

  World journal of gastroenterology 20080628

• Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.

  European journal of clinical investigation 20080601

• [Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20080501

• Diclofenac-bismuth complex: synthesis, physicochemical, and biological evaluation.

  Drug development and industrial pharmacy 20080401

• Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.

  Alimentary pharmacology & therapeutics 20080215

• Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.

  Journal of gastroenterology and hepatology 20080101

• [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease].

  Klinicheskaia meditsina 20080101

• [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].

  Klinicheskaia meditsina 20080101

• [Clinical response to de-nol in peptic ulcer patients].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20080101

• Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.

  Helicobacter 20071201

• Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis.

  World journal of gastroenterology 20071028

• The protective roles of some lichen species on colloidal bismuth subcitrate genotoxicity.

  Toxicology and industrial health 20070901

• A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori.

  Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 20070801

• Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.

  Hepato-gastroenterology 20070601

• Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children.

  Helicobacter 20070401

• [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].

  Terapevticheskii arkhiv 20070101

• New drugs: retapamulin, bismuth subcitrate potassium, and rotigotine.

  Journal of the American Pharmacists Association : JAPhA 20070101

• Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.

  BMC gastroenterology 20070101

• Randomized comparison of two rescue therapies for Helicobacter pylori infection.

  European journal of clinical investigation 20061101

• [Long term results of treatment by simple surgical closure of perforated gastroduodenal ulcer followed by eradication of Helicobacter pylori].

  Annales de chirurgie 20061001

• Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.

  Journal of gastroenterology and hepatology 20061001

• Guidelines in the medical treatment of Helicobacter pylori infection.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20060901

• Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.

  World journal of gastroenterology 20060814

• Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.

  Pharmacy world & science : PWS 20060801

• Azithromycin in one week quadruple therapy for H pylori eradication in Iran.

  World journal of gastroenterology 20060728

• Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.

  World journal of gastroenterology 20060628

• Fabrication of bismuth subcarbonate nanotube arrays from bismuth citrate.

  Chemical communications (Cambridge, England) 20060604

• Efficacy of one-day quadruple therapy for H pylori infection in Chinese patients.

  World journal of gastroenterology 20060521

• Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: a randomized clinical trial.

  European journal of gastroenterology & hepatology 20060501

• Long-term outcomes after Helicobacter pylori eradication with second-line, bismuth-containing quadruple therapy in Korea.

  European journal of gastroenterology & hepatology 20060501

• Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.

  World journal of gastroenterology 20060321

• Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients.

  Alimentary pharmacology & therapeutics 20060315

• Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20060201

• Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.

  Helicobacter 20060201

• Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly.

  Helicobacter 20060201

• Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone.

  Alimentary pharmacology & therapeutics 20051101

• Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.

  Journal of the National Cancer Institute 20050921

• Acute renal failure after overdose of colloidal bismuth subcitrate.

  Pediatric nephrology (Berlin, Germany) 20050901

• Gene expression changes induced by bismuth in a macrophage cell line.

  Cell and tissue research 20050801

• Eradication rate of Helicobacter pylori in dyspeptic patients.

  Medical science monitor : international medical journal of experimental and clinical research 20050401

• [The effect of Helicobacter pylori eradication therapy on bismuth absorption of colloidal bismuth subcitrate].

  Zhonghua nei ke za zhi 20050401

• Helicobacter pylori reinfection rate 3 years after successful eradication.

  Journal of gastroenterology and hepatology 20050301

• Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.

  Helicobacter 20050201

• Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.

  Alimentary pharmacology & therapeutics 20050115

• [Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].

  Klinicheskaia meditsina 20050101

• [Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].

  Terapevticheskii arkhiv 20050101

• [New ultrashort scheme for helicobacter pylori infection eradication using tetracyline, furazolidone and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia].

  Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 20050101

• Effects of bismuth citrate on the viability and function of Leydig cells and testicular macrophages.

  Journal of applied toxicology : JAT 20050101

• [Eradication therapy of Helicobacter pylori--associated diseases: efficacy, safety, pharmacoeconomy].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20050101

• Biochemical response to colloidal bismuth subcitrate: dose-time effect.

  Biological trace element research 20050101

• Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.

  Chinese journal of digestive diseases 20050101

• [Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].

  Klinicheskaia meditsina 20050101

• Long-term recurrence rate after treatment of Helicobacter pylori infection in children and adolescents in Estonia.

  Scandinavian journal of gastroenterology 20041201

• A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20041101

• [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].

  Orvosi hetilap 20041003

• The effect of Helicobacter pylori eradication in patients with functional dyspepsia: assessment of different diagnostic tests.

  The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20040901

• Total family unit Helicobacter pylori eradication and pediatric re-infection rates.

  Helicobacter 20040801

• Inhibition of alcohol dehydrogenase by bismuth.

  Journal of inorganic biochemistry 20040801

• Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline.

  Journal of clinical pharmacology 20040601

• Helicobacter pylori: a historical perspective 1983-2003.

  The New Zealand medical journal 20040521

• Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.

  World journal of gastroenterology 20040301

• Bismuth citrate in the quantification of inorganic phosphate and its utility in the determination of membrane-bound phosphatases.

  Analytical biochemistry 20040101

• Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.

  Alimentary pharmacology & therapeutics 20040101

• [Comparative efficacy of different therapeutic schemes in gastropathies induced by nonsteroid anti-inflammatory drugs].

  Terapevticheskii arkhiv 20040101

• Structure of colloidal bismuth subcitrate (CBS) in dilute HCl: unique assembly of bismuth citrate dinuclear units ([Bi(cit)(2)Bi](2-)).

  Journal of the American Chemical Society 20031015

• Efficacy of different antibiotic regimens for eradication treatment of Helicobacter pylori infection in peptic ulcer disease in Tanzanian patients.

  Tropical doctor 20031001

• Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.

  Archives of internal medicine 20030922

• The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials.

  Gastroenterology 20030801

• Gastrointestinal and systemic uptake of bismuth in mice after oral exposure.

  Pharmacology & toxicology 20030801

• Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.

  Helicobacter 20030801

• A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

  Helicobacter 20030801

• [Failure of Helicobacter pylori eradication--suggestions for further therapy].

  Orvosi hetilap 20030629

• [Helicobacter pylori eradication. Triple or quadruple therapy?, Long or short treatment?].

  Gastroenterologia y hepatologia 20030501

• Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.

  The American journal of gastroenterology 20030301

• [Bismuth subcitrate caused acute renal failure in a child].

  Zhonghua er ke za zhi = Chinese journal of pediatrics 20030201

• [The state of immune system and effects of current therapy and immunomodulators].

  Klinicheskaia meditsina 20030101

• [Effectiveness of using immunomodulators in combined treatment of patients with chronic gastritis and ulcer disease].

  Klinicheskaia meditsina 20030101

• [Microcirculatory disorders in chronic erosions of the stomach].

  Klinicheskaia meditsina 20030101

• In vitro evaluation of Bacopa monniera on anti-Helicobacter pylori activity and accumulation of prostaglandins.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20030101

• [Level of Helicobacter pylori infection of the gastric mucosa in the optimization of a daily dose of antihelicobacter drugs].

  Klinicheskaia meditsina 20030101

• A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study.

  Gastroenterology 20021201

• Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study.

  European journal of gastroenterology & hepatology 20021101

• Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study.

  Helicobacter 20021001

• Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20020801

• One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.

  Alimentary pharmacology & therapeutics 20020701

• Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

  Alimentary pharmacology & therapeutics 20020701

• Bismuth-induced lysosomal rupture in J774 cells.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20020501

• Pathways of proximal tubular cell death in bismuth nephrotoxicity.

  Toxicology and applied pharmacology 20020415

• Bismuth subcitrate nephrotoxicity. A reversible cause of acute oliguric renal failure.

  Nephron 20020401

• Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.

  The American journal of gastroenterology 20020401

• Fanconi's syndrome, acute renal failure, and tonsil ulcerations after colloidal bismuth subcitrate intoxication.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20020301

• [Helicobacter heilmannii-associated gastritis].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy.

  Journal of clinical gastroenterology 20020101

• [Changes in local humoral immunity during stomach ulcer healing with laser and drug therapy].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• Bismuth subcitrate/metronidazole/ tetracycline--Axcan Pharma. Bismuth triple therapy--Axcan Pharma, Helicide.

  Drugs in R&D 20020101

• Human biokinetics of injected bismuth-207.

  Human & experimental toxicology 20011201

• Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011115

• Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.

  Gastroenterology 20011001

• Six-year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease.

  European journal of gastroenterology & hepatology 20011001

• Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20010901

• Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial.

  European journal of gastroenterology & hepatology 20010801

• Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.

  Alimentary pharmacology & therapeutics 20010701

• Helicobacter pylori and iron deficiency anaemia in children.

  Scandinavian journal of gastroenterology 20010701

• Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.

  Alimentary pharmacology & therapeutics 20010601

• Reversible nephrotoxicity after overdose of colloidal bismuth subcitrate.

  Pediatric nephrology (Berlin, Germany) 20010601

• Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?

  Helicobacter 20010601

• Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretory therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection.

  European journal of gastroenterology & hepatology 20010501

• Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.

  The New England journal of medicine 20010329

• Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.

  Annals of internal medicine 20010306

• Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.

  Alimentary pharmacology & therapeutics 20010301

• The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.

  The Israel Medical Association journal : IMAJ 20010301

• Histochemical tracing of bismuth in Helicobacter pylori after in vitro exposure to bismuth citrate.

  Scandinavian journal of gastroenterology 20010201

• Bismuth overdosing-induced reversible nephropathy in rats.

  Archives of toxicology 20010201

• Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.

  The American journal of gastroenterology 20010101

• Survey of dyspepsia management in community.

  Singapore medical journal 20010101

• [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].

  Khirurgiia 20010101

• [How to overcome antibiotic resistance of Helicobacter pylori. Role of de-nol in current schemes of eradication therapy].

  Terapevticheskii arkhiv 20010101

• Randomized trial of a quadruple-drug regimen and a triple-drug regimen for eradication of Helicobacter pylori: long-term follow-up study.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20010101

• Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.

  Digestion 20010101

• Inhibition of inducible nitric oxide synthase in the human intestinal epithelial cell line, DLD-1, by the inducers of heme oxygenase 1, bismuth salts, heme, and nitric oxide donors.

  Gut 20001201

• Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.

  Helicobacter 20000901

• The mode of action of colloidal bismuth subcitrate.

  Scandinavian journal of gastroenterology. Supplement 19910101

• Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

  Drugs 19880801